Rivoceranib plus Camrelizumab for First-Line Treatment of HC

Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.

Related Keywords

Rachna Shroff , , Assessing Liver Function , First Line Treatment , Hcc , Hepatocellular Carcinoma , Liver Function , Patients With Hcc , Patients With Hepatocellular Carcinoma , Liver Function Assessments , Assessing Liver Function In Patients , Risk Factors Hepatocellular Carcinoma , Liver Function Hepatocellular Carcinoma , Hepatocellular Carcinoma Treatments ,